Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

50.65USD
23 Oct 2018
Change (% chg)

$-0.23 (-0.45%)
Prev Close
$50.88
Open
$50.52
Day's High
$51.03
Day's Low
$49.83
Volume
15,369,773
Avg. Vol
6,465,808
52-wk High
$70.05
52-wk Low
$49.83

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $102,645.10
Shares Outstanding(Mil.): 1,631.88
Dividend: 0.40
Yield (%): 2.54

Financials

  BMY Industry Sector
P/E (TTM): 31.25 29.75 32.14
EPS (TTM): 2.01 -- --
ROI: 14.19 13.18 12.83
ROE: 24.44 15.14 14.95

Roche scores win in slowing aggressive type of breast cancer

ZURICH/MUNICH An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.

Oct 20 2018

UPDATE 1-Roche scores win in slowing aggressive type of breast cancer

* Trailing rivals, Roche seeking immunotherapy niches (Adds comments from lead study author, details on PD-L1 subgroup)

Oct 20 2018

CORRECTED-Roche's Tecentriq boosts survival in triple-negative breast cancer

ZURICH/MUNICH, Oct 20 An immunotherapy cocktail from Roche helped slow a type of breast cancer where new treatments have proven elusive, data released on Saturday showed, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.

Oct 20 2018

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

Oct 12 2018

UPDATE 1-Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

Oct 12 2018

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 Bristol-Myers Squibb Co said on Friday its blockbuster cancer drug Opdivo failed to meet the main goal in patients with a type of lung cancer, that had relapsed after chemotherapy.

Oct 12 2018

Bristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.

Oct 11 2018

Bristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV, Oct 11 Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours.

Oct 11 2018

Deals of the day-Mergers and acquisitions

Oct 8 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Oct 08 2018

Stada, buyout funds in race for Bristol-Myers' French business: sources

LONDON German generic drugmaker Stada is vying with a group of European buyout funds for control of Bristol-Myers Squibb's French over-the-counter drugs business, sources familiar with the matter told Reuters.

Oct 08 2018

Earnings vs. Estimates